Stock info Astrazeneca | Filter Basic-Info
Stock: Astrazeneca (UK large caps), ISIN: GB0009895292
| Last Price | 11990.00 | Max Price | 15542.00 |
| Min Price | 10956.00 | 1 Year return | 30.57 |
| Avg. Target | 0.00 | Expected Return | -100.00 % |
| Sector | Health Care | Subsector | Pharmaceuticals |
| Sell | 0 | Rating | |
| Hold | 0 | Concensus | |
| Buy | 0 | ||
| Annual report 2012 |
Loading...
Contact info:Street: 2 Kingdom StreetZip Code: London W2 City: LondonCountry: Great BritainPhone: 44 20 7604 8122Email: IR@astrazeneca.comWebsite: www.astrazeneca.co.uk
Sector Review Astrazeneca
Loading...
| År | Omsättning | Totala sektorer | marknadsandel |
|---|---|---|---|
| 2019 | 184 | 474,848 | 0.04 % |
| 2020 | 195 | 469,560 | 0.04 % |
| 2021 | 277 | 566,739 | 0.05 % |
| 2022 | 367 | 640,095 | 0.06 % |
| 2023 | 360 | 590,728 | 0.06 % |
Advice Astrazeneca
News Astrazeneca
Analysts anticipate for 2024 on revenue increase Astrazeneca, high dividend yield
Tomorrow the English Astrazeneca will publish its past quarters figures. Over the current book year the company from Cambridge's total revenue could be around 52.34 billion GBp (consensus estimates). The expected revenue would be a record for the company. This...
AstraZeneca signs deal to supply Canada 100k doses of COVID antibody therapy Evusheld
. AstraZeneca (NASDAQ:AZN) inked a conditional agreement with Canada to supply 100K doses of its antibody therapy Evusheld for the prevention (pre-exposure prophylaxis) of COVID-19.
The antibody therapy is currently under review by Health Canada for use...
Analysts expect revenue increase Astrazeneca
Tomorrow the English Astrazeneca will publish its past quarter figures. Over the current book year the company from Cambridge's total revenue could be around 43.11 billion GBp (consensus estimates). This is hugely more than 2021's revenue of 37.42 billion GBp....
AstraZeneca teams up with Scorpion Therapeutics to develop cancer treatments
AstraZeneca (NASDAQ:AZN) collaborates with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.
Under terms of the agreement,...
AstraZeneca, Oxford start work on Omicron-specific COVID vaccine
Researchers at AstraZeneca (AZN) and Oxford University have begun work on developing a COVID-19 vaccine that would specifically target the Omicron variant, the Financial Times reports.
An Oxford official told the newspaper that the university and company...
Annual reports Astrazeneca
| 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
Profile Astrazeneca
No Records Found
Results Astrazeneca
| Resultat |
2021
|
2022
|
2023
|
2024
|
2025
|
|---|---|---|---|---|---|
| Intäkter |
|
|
|
|
|
| Kostnader |
|
|
|
|
|
| Vinst |
|
|
|
|
|
| Vinstmarginal |
|
|
|
|
|
| Avkastning på investering |
|
|
|
|
|
Balance Astrazeneca
| Balance |
2021
|
2022
|
2023
|
2024
|
2025
|
|---|---|---|---|---|---|
| Equity |
|
|
|
|
|
| Debt |
|
|
|
|
|
| Total assets |
|
|
|
|
|
| Solvency |
|
|
|
|
|
| Cash |
|
|
|
|
|
| Cashflow |
|
|
|
|
|
| Employees |
|
|
|
|
|
| Revenue per employee |
|
|
|
|
|
| Cashflow / Debt |
|
|
|
|
|
Details Astrazeneca
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
4437.50
|
5121.00
|
5873.00
|
7607.00
|
7324.00
|
| Eps |
2.24
|
1.75
|
1.33
|
0.77
|
1.78
|
| Price/earnings-ratio |
1981.03
|
2926.29
|
4415.79
|
9879.22
|
7084.27
|
| Dividend |
2.19
|
2.02
|
2.15
|
2.18
|
2.07
|
| Dividend % |
0.05 %
|
0.04 %
|
0.04 %
|
0.03 %
|
0.02 %
|
| Payout % |
0.98
|
1.15
|
1.62
|
2.83
|
1.16
|
| Book value |
0.10
|
0.09
|
0.08
|
0.08
|
0.09
|
| Market to book |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Cashflow per stock |
0.03
|
0.02
|
0.02
|
0.02
|
0.03
|
| Stocks |
1,265
|
1,266
|
1,267
|
1,312
|
1,313
|
| Market Cap |
5.614.455.55
|
6.484.320.86
|
7.441.325.92
|
9.981.448.98
|
16.552.768.70
|
Dividend Astrazeneca
Price info Astrazeneca
|
Date
|
Price
|
|---|---|
|
11 Aug 2026
|
11990.00
|
|
07 Aug 2026
|
11850.00
|
|
06 Aug 2026
|
12036.00
|
|
28 Jul 2026
|
12888.00
|
|
14 Jul 2026
|
12610.00
|
|
10 Jul 2026
|
12834.00
|
|
09 Jul 2026
|
13354.00
|
|
08 Jul 2026
|
14240.00
|
|
07 Jul 2026
|
14364.00
|
|
06 Jul 2026
|
14100.00
|
|
03 Jul 2026
|
14456.00
|
|
02 Jul 2026
|
14538.00
|
|
01 Jul 2026
|
13854.00
|
|
30 Jun 2026
|
14100.00
|
|
29 Jun 2026
|
14298.00
|
|
26 Jun 2026
|
14318.00
|
|
25 Jun 2026
|
14062.00
|
|
24 Jun 2026
|
13910.00
|
|
23 Jun 2026
|
13590.00
|
|
22 Jun 2026
|
13290.00
|
|
19 Jun 2026
|
13234.00
|
|
18 Jun 2026
|
13154.00
|
|
17 Jun 2026
|
13472.00
|
|
16 Jun 2026
|
13284.00
|
|
15 Jun 2026
|
13200.00
|
|
12 Jun 2026
|
13462.00
|
|
11 Jun 2026
|
13578.00
|
|
10 Jun 2026
|
13464.00
|
|
09 Jun 2026
|
13632.00
|
|
08 Jun 2026
|
13796.00
|
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x |
©2026 ValueSpectrum. All Rights Reserved
Developed and maintained by 